Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated...

Area of Science:

• Endocrinology
• Bone Metabolism
• Oncology

Background:

• Hypercalcemia in primary hyperparathyroidism (1° HPT), humoral hypercalcemia of malignancy (HHM), and local osteolytic hypercalcemia (LOH) involves complex bone and vitamin D alterations.
• Understanding these differences is crucial for accurate diagnosis and treatment.

Purpose of the Study:

• To compare bone resorption and formation markers, and vitamin D metabolism in patients with 1° HPT, HHM, and LOH.
• To investigate the relationship between bone remodeling markers and serum 1,25-dihydroxyvitamin D levels.

Main Methods:

• Analysis of serum calcium, bone resorption markers (total deoxypyridinoline - Dpyd), bone formation markers (osteocalcin - OC), and 1,25-dihydroxyvitamin D [1,25(OH)2D].
• Comparison of T scores for Dpyd and OC, and calculation of Dpyd/OC ratios.
• Assessment of vitamin D status in relation to serum calcium levels.

Main Results:

• Bone resorption markers (Dpyd) were highest in HHM, significantly exceeding those in 1° HPT.
• Bone formation markers (OC) were highest in 1° HPT, while suppressed in HHM.
• 1,25(OH)2D was elevated in 1° HPT but suppressed in HHM and LOH, irrespective of serum calcium levels.

Conclusions:

• 1° HPT demonstrates coupled bone formation and resorption, unlike HHM and LOH, where remodeling is uncoupled.
• The Dpyd/OC ratio serves as a useful index for assessing bone remodeling coupling.
• Tumor-secreted cytokines may explain the distinct bone and vitamin D metabolic profiles in HHM and LOH compared to 1° HPT.